Bolatbek Baimakhanov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bolatbek Baimakhanov has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Sh Kaniyev
National Scientific Center of Surgery named after A. N. Syzganov, Almaty, KAZAKHSTAN
7 shared publications - A. T. Chormanov
“Central City Clinical Hospital”, Almaty, Kazakhstan
6 shared publications - Maxat Doskhanov
National Scientific Center for Surgery named after A.N. Syzganov
6 shared publications - E. K. Nurlanbayev
“A. N. Syzganov National Scientific Center for Surgery” JSC
4 shared publications - Zh. B. Baimakhanov
National Scientific Center of Surgery named after A.N. Syzganov, Almaty, Kazakhstan
4 shared publications - Onlassyn Ibekenov
Kazakh National Medical University Named After S.D. Asfendiyarov, Almaty, Republic of Kazakhstan
3 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Australasia Publishing Group in Central Asian Journal of Nephrology
- Vol. 2 (2, Suppl. ) , cajn_A20
Clinical Outcomes of Kidney Transplantation at the Syzganov National Scientific Center of Surgery: A Retrospective Cohort Study
Introduction: Kidney transplantation has been actively developing in Kazakhstan, data on outcomes remain limited. This study aimed to evaluate recipient characteristics, patient survival, causes of ESKD, and renal graft function after KT. Methods: We retrospectively analyzed 37 consecutive kidney transplant recipients who underwent KT between January 2020 and July 2025. Body mass index (BMI), etiology of ESKD, donor type, pre-transplant hemodialysis, mortality, and renal graft function were evaluated. Renal graft function was assessed using serial serum creatinine measurements during follow-up. Some recipients were lost to follow-up, which limited assessment of long-term graft function in these patients. Results: In the available follow-up data, renal function was generally satisfactory and remained stable in most recipients with observations. Graft survival was 86.5%, with graft loss documented in five recipients: three surviving recipients experienced rejection-associated graft loss, and two patients died following rejection. Among the five deaths, two were associated with confirmed COVID-19 infection, one was attributed to cerebral infarction caused by cerebral arterial thrombosis, and two were related to graft rejection. Among the three recipients with rejection-related complications, all experienced adverse effects associated with immunosuppressive therapy, including significant infectious complications. Discussion: An important consideration is that the study period overlapped with the COVID-19 pandemic. Registry data showed substantially increased infection-related mortality among kidney transplant recipients receiving chronic immunosuppression during 2020, with infection and COVID-19 accounting for a major proportion of excess deaths. Therefore, mortality and survival outcomes should be interpreted in the context of the pandemic, limiting direct comparison with pre-COVID-19 cohorts. Conclusion: Kidney transplantation at our center demonstrated favorable medium-term outcomes, with improvement in renal function and satisfactory outcomes in most recipients. Overall patient survival was 86.5%, and graft survival was also 86.5%. Continued monitoring of immunosuppression-therapy, complications, and long-term follow-up is important for improving patient and graft outcomes.
- 7 October 2026
- Published by Australasia Publishing Group in Central Asian Journal of Nephrology
- Vol. 2 (2, Suppl. ) , cajn_A20
Open AccessClinical Outcomes of Kidney Transplantation at the Syzganov National Scientific Center of Surgery: A Retrospective Cohort Study
Introduction: Kidney transplantation has been actively developing in Kazakhstan, data on outcomes remain limited. This study aimed to evaluate recipient characteristics, patient survival, causes of ESKD, and renal graft function after KT. Methods: We retrospectively analyzed 37 consecutive kidney transplant recipients who underwent KT between January 2020 and July 2025. Body mass index (BMI), etiology of ESKD, donor type, pre-transplant hemodialysis, mortality, and renal graft function were evaluated. Renal graft function was assessed using serial serum creatinine measurements during follow-up. Some recipients were lost to follow-up, which limited assessment of long-term graft function in these patients. Results: In the available follow-up data, renal function was generally satisfactory and remained stable in most recipients with observations. Graft survival was 86.5%, with graft loss documented in five recipients: three surviving recipients experienced rejection-associated graft loss, and two patients died following rejection. Among the five deaths, two were associated with confirmed COVID-19 infection, one was attributed to cerebral infarction caused by cerebral arterial thrombosis, and two were related to graft rejection. Among the three recipients with rejection-related complications, all experienced adverse effects associated with immunosuppressive therapy, including significant infectious complications. Discussion: An important consideration is that the study period overlapped with the COVID-19 pandemic. Registry data showed substantially increased infection-related mortality among kidney transplant recipients receiving chronic immunosuppression during 2020, with infection and COVID-19 accounting for a major proportion of excess deaths. Therefore, mortality and survival outcomes should be interpreted in the context of the pandemic, limiting direct comparison with pre-COVID-19 cohorts. Conclusion: Kidney transplantation at our center demonstrated favorable medium-term outcomes, with improvement in renal function and satisfactory outcomes in most recipients. Overall patient survival was 86.5%, and graft survival was also 86.5%. Continued monitoring of immunosuppression-therapy, complications, and long-term follow-up is important for improving patient and graft outcomes.
- Open Access
- 27 September 2026
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 23 (5) , em752
Modified allogeneic great saphenous vein cold-stored in custodiol for neo-MHV reconstruction in right-lobe living-donor liver transplantation: Early patency in a single-center retrospective cohort
In right-lobe living-donor liver transplantation (LDLT), adequate venous outflow of the anterior sector (V5/V8 tributaries) is critical to prevent congestion and early graft dysfunction. The choice of conduit for V5/V8 outflow reconstruction with creation of a neo-middle hepatic vein (MHV) remains a practical limitation, especially in the setting of a shortage of deceased-donor vascular allografts. The aim of this study was to describe the technical feasibility and early patency of a modified allogeneic great saphenous vein (GSV) cold-stored in custodiol and to explore its outcomes relative to recipient portal vein and prosthetic conduit cohorts. We conducted a retrospective single-center comparative cohort study covering the period from 2014 to 2025. Adult recipients aged 18-60 years who underwent right-lobe LDLT with V5 and/or V8 outflow reconstruction using a neo-MHV conduit were included: recipient PV (n = 63), prosthesis (n = 11), modified GSV (n = 16). The primary endpoint was obstruction of the re-constructed V5/V8 outflow through the neo-MHV conduit within 45 days, classified as early (≤ 7 days) or late ( > 7 days). Patency was assessed by serial Doppler ultrasound and/or contrast-enhanced imaging. Time-to-event analysis was performed using the Kaplan-Meier method. Overall outflow obstruction within 45 days was observed in 25.4% of the recipient PV group, 45.5% of the prosthesis group, and 6.2% of the modified GSV group (p = 0.063). In an exploratory Firth logistic regression adjusted for calendar year and selected baseline and graft characteristics, the overall association between conduit type and 45-day outflow obstruction was not statistically significant (p = 0.318). The probability of obstruction-free patency on day 7 was 0.804, 0.727, and 0.938, respectively; by day 45, it was 0.733, 0.468, and 0.938, respectively. Observed group-level differences included shorter cold ischemia time (38 [35; 42] min; p = 0.001), a shorter anhepatic period (42 [26; 61] min; p < 0.001), and lower blood loss (1,200 [775; 1,500] mL; p = 0.006) in the modified GSV group. Postoperative hospital stay was also shorter (18 [15; 21] days; p = 0.011), and peak AST, ALT, and INR values were lower (p = 0.039, p = 0.021, and p = 0.027, respectively). The rate of any postoperative complications did not differ significantly (p = 0.439). In-hospital mortality was 19.0% in the recipient PV group, 36.4% in the prosthesis group, and 0% in the modified GSV group (p = 0.053). In this retrospective and temporally heterogeneous cohort, modified allogeneic GSV was technically feasible and demonstrated encouraging early neo-MHV conduit patency. Because conduit allocation was non-random, the groups were small and noncontemporaneous, and important baseline and procedural differences were present, the observed associations cannot be attributed to conduit materi-al and do not establish superiority. Further prospective evaluation is warranted.
- 27 September 2026
- Published by Modestum Ltd in Electronic Journal of General Medicine
- Vol. 23 (5) , em752
Open AccessModified allogeneic great saphenous vein cold-stored in custodiol for neo-MHV reconstruction in right-lobe living-donor liver transplantation: Early patency in a single-center retrospective cohort
In right-lobe living-donor liver transplantation (LDLT), adequate venous outflow of the anterior sector (V5/V8 tributaries) is critical to prevent congestion and early graft dysfunction. The choice of conduit for V5/V8 outflow reconstruction with creation of a neo-middle hepatic vein (MHV) remains a practical limitation, especially in the setting of a shortage of deceased-donor vascular allografts. The aim of this study was to describe the technical feasibility and early patency of a modified allogeneic great saphenous vein (GSV) cold-stored in custodiol and to explore its outcomes relative to recipient portal vein and prosthetic conduit cohorts. We conducted a retrospective single-center comparative cohort study covering the period from 2014 to 2025. Adult recipients aged 18-60 years who underwent right-lobe LDLT with V5 and/or V8 outflow reconstruction using a neo-MHV conduit were included: recipient PV (n = 63), prosthesis (n = 11), modified GSV (n = 16). The primary endpoint was obstruction of the re-constructed V5/V8 outflow through the neo-MHV conduit within 45 days, classified as early (≤ 7 days) or late ( > 7 days). Patency was assessed by serial Doppler ultrasound and/or contrast-enhanced imaging. Time-to-event analysis was performed using the Kaplan-Meier method. Overall outflow obstruction within 45 days was observed in 25.4% of the recipient PV group, 45.5% of the prosthesis group, and 6.2% of the modified GSV group (p = 0.063). In an exploratory Firth logistic regression adjusted for calendar year and selected baseline and graft characteristics, the overall association between conduit type and 45-day outflow obstruction was not statistically significant (p = 0.318). The probability of obstruction-free patency on day 7 was 0.804, 0.727, and 0.938, respectively; by day 45, it was 0.733, 0.468, and 0.938, respectively. Observed group-level differences included shorter cold ischemia time (38 [35; 42] min; p = 0.001), a shorter anhepatic period (42 [26; 61] min; p < 0.001), and lower blood loss (1,200 [775; 1,500] mL; p = 0.006) in the modified GSV group. Postoperative hospital stay was also shorter (18 [15; 21] days; p = 0.011), and peak AST, ALT, and INR values were lower (p = 0.039, p = 0.021, and p = 0.027, respectively). The rate of any postoperative complications did not differ significantly (p = 0.439). In-hospital mortality was 19.0% in the recipient PV group, 36.4% in the prosthesis group, and 0% in the modified GSV group (p = 0.053). In this retrospective and temporally heterogeneous cohort, modified allogeneic GSV was technically feasible and demonstrated encouraging early neo-MHV conduit patency. Because conduit allocation was non-random, the groups were small and noncontemporaneous, and important baseline and procedural differences were present, the observed associations cannot be attributed to conduit materi-al and do not establish superiority. Further prospective evaluation is warranted.
- 31 March 2026
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 22 (1) , 41
OUR EXPERIENCE WITH LAPAROSCOPIC LIVER RESECTION FOR VARIOUS LIVER PATHOLOGIES
Background: Laparoscopic liver resection is a minimally invasive procedure that offers reduced surgical trauma, decreased blood loss, and faster recovery compared with open liver surgery. This study evaluated clinical safety and effectiveness of laparoscopic liver resection in a high-volume surgical center. Materials and Methods: A retrospective review included 471 liver resections carried out from 2017 to April 2025. The cohort consisted of 107 laparoscopic operations and 364 open operations. Patient demographic characteristics, operative parameters, postoperative hospital stay, and complication rates were analyzed. Surgical indications comprised echinococcosis, alveococcosis, focal nodular hyperplasia, hepatic hemangioma, hepatocellular carcinoma, metastatic liver tumors, cystadenoma, and polycystic liver disease. Results: Laparoscopic surgery showed significantly shorter operative duration (224.5 minutes versus 380 minutes), reduced intraoperative blood loss (147 milliliters versus 293 milliliters), and shorter hospitalization (5.3 days versus 10 days). Postoperative complications occurred in 0.9 percent after laparoscopic procedures and in 4.1 percent after open procedures. No deaths were recorded following laparoscopic surgery, while postoperative mortality in the open group reached 1.37 percent. Laparoscopic liver resection was predominantly used for atypical peripheral liver resections and resections of the left lateral section, whereas major and extended liver resections remained more common with open access. Conclusion: Laparoscopic liver resection demonstrated high safety, favorable perioperative outcomes, and strong clinical effectiveness, supporting further expansion of minimally invasive approaches in hepatobiliary surgery.
- 31 March 2026
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 22 (1) , 41
OUR EXPERIENCE WITH LAPAROSCOPIC LIVER RESECTION FOR VARIOUS LIVER PATHOLOGIES
Background: Laparoscopic liver resection is a minimally invasive procedure that offers reduced surgical trauma, decreased blood loss, and faster recovery compared with open liver surgery. This study evaluated clinical safety and effectiveness of laparoscopic liver resection in a high-volume surgical center. Materials and Methods: A retrospective review included 471 liver resections carried out from 2017 to April 2025. The cohort consisted of 107 laparoscopic operations and 364 open operations. Patient demographic characteristics, operative parameters, postoperative hospital stay, and complication rates were analyzed. Surgical indications comprised echinococcosis, alveococcosis, focal nodular hyperplasia, hepatic hemangioma, hepatocellular carcinoma, metastatic liver tumors, cystadenoma, and polycystic liver disease. Results: Laparoscopic surgery showed significantly shorter operative duration (224.5 minutes versus 380 minutes), reduced intraoperative blood loss (147 milliliters versus 293 milliliters), and shorter hospitalization (5.3 days versus 10 days). Postoperative complications occurred in 0.9 percent after laparoscopic procedures and in 4.1 percent after open procedures. No deaths were recorded following laparoscopic surgery, while postoperative mortality in the open group reached 1.37 percent. Laparoscopic liver resection was predominantly used for atypical peripheral liver resections and resections of the left lateral section, whereas major and extended liver resections remained more common with open access. Conclusion: Laparoscopic liver resection demonstrated high safety, favorable perioperative outcomes, and strong clinical effectiveness, supporting further expansion of minimally invasive approaches in hepatobiliary surgery.
- 31 March 2026
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 22 (1) , 50
UPDATES ON SURGICAL CARE FOR OBESITY IN KAZAKHSTAN: A SINGLE CENTER RETROSPECTIVE COHORT STUDY OF BARIATRIC SURGERY OUTCOMES
Background: Aim of this study is to present results and evaluate mid-term outcomes on using of three bariatric procedures - laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, and One Anastomosis Gastric Bypass in the Kazakhstani population. According to the World Obesity Federation Kazakhstan is among countries that has high obesity rates, however there are not enough mechanisms in place to regulate it and there is still limited access to bariatric surgery. Materials and Method: This study employed retrospective design. Patients undergoing bariatric surgery at the Syzganov National Scientific Center of Surgery between January 2018 and December 2023 were consecutively recruited for the study. Result: The primary outcomes of this study were the percentages of excess weight loss and total weight loss at 1-, 3-, 6-, and 12-months post-surgery. Secondary outcomes included perioperative adverse events for each surgical group and improvement in obesity-related medical conditions. The findings demonstrate the potential of surgical interventions to address the growing burden of obesity and its metabolic consequences. Conclusion: While all procedures demonstrated efficacy, laparoscopic sleeve gastrectomy was associated with rapid reductions in BMI and excess weight loss, while Roux-en-Y gastric bypass achieved greater absolute weight loss over time. One Anastomosis Gastric Bypass offered a balanced alternative, though it showed an increased incidence of gallstone formation. The demonstrated efficacy of bariatric surgery supports its inclusion in mandatory health insurance coverage in Kazakhstan, potentially improving patient access and reducing long-term healthcare costs associated with obesity-related comorbidities.
- 31 March 2026
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 22 (1) , 50
UPDATES ON SURGICAL CARE FOR OBESITY IN KAZAKHSTAN: A SINGLE CENTER RETROSPECTIVE COHORT STUDY OF BARIATRIC SURGERY OUTCOMES
Background: Aim of this study is to present results and evaluate mid-term outcomes on using of three bariatric procedures - laparoscopic sleeve gastrectomy, Roux-en-Y gastric bypass, and One Anastomosis Gastric Bypass in the Kazakhstani population. According to the World Obesity Federation Kazakhstan is among countries that has high obesity rates, however there are not enough mechanisms in place to regulate it and there is still limited access to bariatric surgery. Materials and Method: This study employed retrospective design. Patients undergoing bariatric surgery at the Syzganov National Scientific Center of Surgery between January 2018 and December 2023 were consecutively recruited for the study. Result: The primary outcomes of this study were the percentages of excess weight loss and total weight loss at 1-, 3-, 6-, and 12-months post-surgery. Secondary outcomes included perioperative adverse events for each surgical group and improvement in obesity-related medical conditions. The findings demonstrate the potential of surgical interventions to address the growing burden of obesity and its metabolic consequences. Conclusion: While all procedures demonstrated efficacy, laparoscopic sleeve gastrectomy was associated with rapid reductions in BMI and excess weight loss, while Roux-en-Y gastric bypass achieved greater absolute weight loss over time. One Anastomosis Gastric Bypass offered a balanced alternative, though it showed an increased incidence of gallstone formation. The demonstrated efficacy of bariatric surgery supports its inclusion in mandatory health insurance coverage in Kazakhstan, potentially improving patient access and reducing long-term healthcare costs associated with obesity-related comorbidities.
- 31 December 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 85 (4) , 94
BILIOPANCREATIC LOOP LENGTH IN ONE-ANASTOMOSIS GASTRIC BYPASS: A LITERATURE REVIEW
One-anastomosis gastric bypass is currently a common procedure in bariatric and metabolic surgery. This procedure, based on a single-loop gastroenteric anastomosis (biliopancreatic loop) with a long, narrow stomach, has a mixed mechanism of action (restriction and malabsorption). However, the biliopancreatic loop, and in particular its length, is considered responsible for the degree of malabsorption, but the most appropriate or "optimal" biliopancreatic loop length remains a subject of debate. This literature review examines the relationship between biliopancreatic loop length, selected using various methods, and postoperative weight loss and nutritional deficiencies.
- 31 December 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 85 (4) , 94
BILIOPANCREATIC LOOP LENGTH IN ONE-ANASTOMOSIS GASTRIC BYPASS: A LITERATURE REVIEW
One-anastomosis gastric bypass is currently a common procedure in bariatric and metabolic surgery. This procedure, based on a single-loop gastroenteric anastomosis (biliopancreatic loop) with a long, narrow stomach, has a mixed mechanism of action (restriction and malabsorption). However, the biliopancreatic loop, and in particular its length, is considered responsible for the degree of malabsorption, but the most appropriate or "optimal" biliopancreatic loop length remains a subject of debate. This literature review examines the relationship between biliopancreatic loop length, selected using various methods, and postoperative weight loss and nutritional deficiencies.
- 31 December 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 85 (4) , 73
PORTAL FLOW MODULATION IN LIVING DONOR LIVER TRANSPLANTATION
Background: Small-for-size syndrome is one of the major causes of graft dysfunction after living donor liver transplantation in adults. Excessive portal inflow leading to sinusoidal hyperperfusion and impaired graft function is the primary mechanism of this complication. Effective prevention requires not only morphometric evaluation of the graft but also strict control of portal hemodynamics. Aim of the study is evaluate the effectiveness of graft inflow modulation and determine the prognostic significance of graft-to-recipient weight ratio, spleen-to-graft volume ratio, portal venous flow, and portal venous pressure. Materials and Methods: This study included adult patients who underwent living donor liver transplantation from 2011 to 2025. Portal hemodynamics was assessed intraoperatively. Graft inflow modulation was performed upon detection of portal hyperperfusion( p< 0.05). Results: Patients with small graft volume demonstrated elevated portal venous flow and pressure prior to intervention. Inflow modulation effectively reduced portal venous pressure to physiological levels and was associated with a lower incidence of small-for-size syndrome and reduced mortality. A spleen-to-graft volume ratio greater than 1.0 was linked to significant hyperperfusion and poorer clinical outcomes. Intraoperative modulation proved markedly more effective than delayed postoperative interventions, resulting in higher survival rates and an absence of severe graft dysfunction. Conclusion: Excessive portal inflow is the key determinant of graft dysfunction in living donor liver transplantation. Timely intraoperative modulation of portal blood flow improves hemodynamic stability and enhances survival. A combined assessment of morphometric and hemodynamic parameters enables optimal prevention of small-forsize syndrome and supports a personalized transplantation approach.
- 31 December 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY OF KAZAKHSTAN
- Vol. 85 (4) , 73
PORTAL FLOW MODULATION IN LIVING DONOR LIVER TRANSPLANTATION
Background: Small-for-size syndrome is one of the major causes of graft dysfunction after living donor liver transplantation in adults. Excessive portal inflow leading to sinusoidal hyperperfusion and impaired graft function is the primary mechanism of this complication. Effective prevention requires not only morphometric evaluation of the graft but also strict control of portal hemodynamics. Aim of the study is evaluate the effectiveness of graft inflow modulation and determine the prognostic significance of graft-to-recipient weight ratio, spleen-to-graft volume ratio, portal venous flow, and portal venous pressure. Materials and Methods: This study included adult patients who underwent living donor liver transplantation from 2011 to 2025. Portal hemodynamics was assessed intraoperatively. Graft inflow modulation was performed upon detection of portal hyperperfusion( p< 0.05). Results: Patients with small graft volume demonstrated elevated portal venous flow and pressure prior to intervention. Inflow modulation effectively reduced portal venous pressure to physiological levels and was associated with a lower incidence of small-for-size syndrome and reduced mortality. A spleen-to-graft volume ratio greater than 1.0 was linked to significant hyperperfusion and poorer clinical outcomes. Intraoperative modulation proved markedly more effective than delayed postoperative interventions, resulting in higher survival rates and an absence of severe graft dysfunction. Conclusion: Excessive portal inflow is the key determinant of graft dysfunction in living donor liver transplantation. Timely intraoperative modulation of portal blood flow improves hemodynamic stability and enhances survival. A combined assessment of morphometric and hemodynamic parameters enables optimal prevention of small-forsize syndrome and supports a personalized transplantation approach.
- 1 October 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- Vol. 21 (3) , 4-9
ACUTE LIVER FAILURE ON THE BACKGROUND OF CHRONIC LIVER DISEASE DUE TO HEPATITIS VIRUS REACTIVATION
Today, hepatitis B virus-associated acute liver failure remains the leading cause of liver failure (44% mortality in Asia and 41% in the United States). Studies show that among patients with hepatitis B-associated cirrhosis, acute liver failure develops in 10-20% of cases. Acute liver failure on chronic liver disease is a potentially reversible syndrome that occurs in patients with cirrhosis or chronic liver disease and is characterized by acute decompensation, organ failure, and high short-term mortality. Chronic hepatitis B virus infection is a leading cause of liver morbidity and mortality worldwide. When we talk about hepatitis B, there is a high risk of developing super infection hepatitis D, since hepatitis D remains infectious and can reactivate at very low titers that are not detected using modern analysis methods if HBsAg remains in the blood serum. The interaction of these viruses leads to accelerated progression of fibrosis and cirrhosis of the liver, which significantly increases the risk of developing acute liver failure against the background of chronic. In our case, a patient diagnosed with liver cirrhosis as a result of viral hepatitis B with delta agent, class C according to Child–Pugh–Turcotte, MELD-36 points, the patient developed a severe form of acute renal failure, which required emergency intervention, so he was not included in the waiting list for a transplant from a cadaveric donor. His wife became the donor, which is an example of living donation, which provides higher chances of successful recovery due to a shorter waiting time and a lower risk of graft rejection. Timely examination of the donor and recipient, as well as prompt liver transplantation, contributed to a favorable outcome of the disease.
- 1 October 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- Vol. 21 (3) , 4-9
ACUTE LIVER FAILURE ON THE BACKGROUND OF CHRONIC LIVER DISEASE DUE TO HEPATITIS VIRUS REACTIVATION
Today, hepatitis B virus-associated acute liver failure remains the leading cause of liver failure (44% mortality in Asia and 41% in the United States). Studies show that among patients with hepatitis B-associated cirrhosis, acute liver failure develops in 10-20% of cases. Acute liver failure on chronic liver disease is a potentially reversible syndrome that occurs in patients with cirrhosis or chronic liver disease and is characterized by acute decompensation, organ failure, and high short-term mortality. Chronic hepatitis B virus infection is a leading cause of liver morbidity and mortality worldwide. When we talk about hepatitis B, there is a high risk of developing super infection hepatitis D, since hepatitis D remains infectious and can reactivate at very low titers that are not detected using modern analysis methods if HBsAg remains in the blood serum. The interaction of these viruses leads to accelerated progression of fibrosis and cirrhosis of the liver, which significantly increases the risk of developing acute liver failure against the background of chronic. In our case, a patient diagnosed with liver cirrhosis as a result of viral hepatitis B with delta agent, class C according to Child–Pugh–Turcotte, MELD-36 points, the patient developed a severe form of acute renal failure, which required emergency intervention, so he was not included in the waiting list for a transplant from a cadaveric donor. His wife became the donor, which is an example of living donation, which provides higher chances of successful recovery due to a shorter waiting time and a lower risk of graft rejection. Timely examination of the donor and recipient, as well as prompt liver transplantation, contributed to a favorable outcome of the disease.
- 1 October 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- Vol. 21 (3) , 96-114
BILE DUCT ATRESIA. LITERATURE REVIEW
Biliary atresia is a rare but severe congenital disease characterized by progressive obstruction of the extrahepatic and intrahepatic bile ducts and leading to cholestasis, fibrosis and cirrhosis of the liver in newborns. Epidemiological data demonstrate the variability of prevalence in different regions, which indicates the possible influence of genetic and environmental factors. The pathogenesis of the disease remains the subject of active study and includes the interaction of immune, viral and molecular mechanisms leading to damage to the bile ducts. Clinical diagnosis is difficult due to non-specific symptoms such as jaundice, light feces, and dark urine, which makes early detection critical to improve outcomes. Surgical intervention, known as Kasai surgery, remains the main treatment method and is aimed at restoring bile outflow, however, a significant proportion of patients eventually require liver transplantation. Current research focuses on the search for biomarkers for early diagnosis, the study of molecular targets, and the development of innovative therapeutic approaches, including immunomodulation and cellular technologies. The literature data emphasize the need for an integrated approach to disease management and further scientific research to improve clinical outcomes.
- 1 October 2025
- Published by National Scientific Center of Surgery named after A.N. Syzganov in BULLETIN OF SURGERY IN KAZAKHSTAN
- Vol. 21 (3) , 96-114
BILE DUCT ATRESIA. LITERATURE REVIEW
Biliary atresia is a rare but severe congenital disease characterized by progressive obstruction of the extrahepatic and intrahepatic bile ducts and leading to cholestasis, fibrosis and cirrhosis of the liver in newborns. Epidemiological data demonstrate the variability of prevalence in different regions, which indicates the possible influence of genetic and environmental factors. The pathogenesis of the disease remains the subject of active study and includes the interaction of immune, viral and molecular mechanisms leading to damage to the bile ducts. Clinical diagnosis is difficult due to non-specific symptoms such as jaundice, light feces, and dark urine, which makes early detection critical to improve outcomes. Surgical intervention, known as Kasai surgery, remains the main treatment method and is aimed at restoring bile outflow, however, a significant proportion of patients eventually require liver transplantation. Current research focuses on the search for biomarkers for early diagnosis, the study of molecular targets, and the development of innovative therapeutic approaches, including immunomodulation and cellular technologies. The literature data emphasize the need for an integrated approach to disease management and further scientific research to improve clinical outcomes.
- Open Access
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 12-30
International consensus on diagnosing and managing pancreatic serous and mucinous cystic neoplasms
In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 12-30
Open AccessInternational consensus on diagnosing and managing pancreatic serous and mucinous cystic neoplasms
In 2023, with the approval of the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, a consensus study was initiated and conducted on the diagnosis, management, and follow-up of patients with serous and mucinous neoplasms of the pancreas. Based on an extensive literature review, responses to each of the 22 questions posed were formulated and compiled into a Consensus Document. A total of 44 experts representing 27 institutions across 9 countries participated in the preparation of the Consensus. The Delphi method was employed for voting, and ultimately, including the results of votes on selected statements during the final conference, consensus was achieved on all questions.
- Open Access
- 27 June 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (2) , 83-92
Registry of patients with post-traumatic bile duct strictures: results of 8 years of work
In memory of L.I. Kurmanseitova, the initiator of this patient registry In 2016, an initiative group, in coordination with the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, established the "Registry of Patients with Post-Traumatic Bile Duct Strictures" with the aim of assessing long-term treatment outcomes and developing unified approaches to the management of patients with benign bile duct strictures and biliodigestive anastomoses. The registry was officially registered as a federal database. From 2016 to 2024, data on 426 patients were entered into the registry. In 72.8% of patients, the stricture developed after surgeries on the gallbladder and bile ducts. According to the registry data, 33.2% of patients underwent surgical treatment, 33.9% received interventional radiology procedures, 14.4% were treated endoscopically, and 17.8% underwent combined treatment methods. Long-term outcome data were available for 47.3% of patients. This work presents an analysis of treatment outcomes in this patient population based on the registry data. Further development of the registry with an expanded and more detailed database is planned, which will enable more in-depth and high-quality analysis, including the use of artificial intelligence.
- 27 June 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (2) , 83-92
Open AccessRegistry of patients with post-traumatic bile duct strictures: results of 8 years of work
In memory of L.I. Kurmanseitova, the initiator of this patient registry In 2016, an initiative group, in coordination with the leadership of the Hepato-Pancreato-Biliary Association of Commonwealth of Independent States, established the "Registry of Patients with Post-Traumatic Bile Duct Strictures" with the aim of assessing long-term treatment outcomes and developing unified approaches to the management of patients with benign bile duct strictures and biliodigestive anastomoses. The registry was officially registered as a federal database. From 2016 to 2024, data on 426 patients were entered into the registry. In 72.8% of patients, the stricture developed after surgeries on the gallbladder and bile ducts. According to the registry data, 33.2% of patients underwent surgical treatment, 33.9% received interventional radiology procedures, 14.4% were treated endoscopically, and 17.8% underwent combined treatment methods. Long-term outcome data were available for 47.3% of patients. This work presents an analysis of treatment outcomes in this patient population based on the registry data. Further development of the registry with an expanded and more detailed database is planned, which will enable more in-depth and high-quality analysis, including the use of artificial intelligence.